Ascletis Pharma, Inc. · HKEX:1672

Ascletis Pharma — EASD 2025

14 slides from Ascletis Pharma's conference presentation, Sep 16, 2025

  1. Slide 1: ASC30, an Oral GLP-1R Biased Small Molecule Agonist Demonstrated Superior Weigh Loss in Participants with Obesity

    ASC30, an Oral GLP-1R Biased Small Molecule Agonist Demonstrated Superior Weigh Loss in Participants with Obesity: A 28-Day Multiple Ascending Dose Study Jinzi Jason Wu Vanessa Wang Ascletis Pharma (China) Co., Limited, Hong Kong

  2. Slide 2: Disclosure

    Disclosure Dr. Jinzi Jason Wu, presenter, is an employee of Ascletis Pharma (China) Co., Limited, Hong Kong 2

  3. Slide 3: Overview of ASC30

    Overview of ASC30  ASC30 is discovered and developed in-house at Ascletis as a first and only investigational small molecule GLP-1R fully biased agonist designed to be administered:  Once-daily oral tablet  Once-monthly SQ injection as a treatment therapy  Once-quarterly SQ injection as a mainte

  4. Slide 4: "Chugai Scaffold": Only four players in the clinical development

    “Chugai Scaffold”: Only four players in the clinical development* Drug Sponsor Structure Clinical Status Orforglipron Eli Lilly Phase III ASC30** Ascletis Phase II Aleniglipron Structure Therapeutics Phase II (GSBR-1290) Elecoglipron AZ/Eccogene Phase I (AZD5004) *From www.clinicaltrials.gov as of 1

  5. Slide 5: ASC30 oral exposure is much higher than orforglipron in NHP

    ASC30 oral exposure is much higher than orforglipron in NHP (Head-to-head comparison) 5 mg/kg in Rat, 15mg/kg in NHP, Oral dosing AUC0-48h, h*ng/mL AUC0-24h, h*ng/mL ASC30 91,858 8,097 Orforglipron 6,346 1,661 AUC ratio of ASC30 to 14 5 orforglipron 5

  6. Slide 6: ASC30 tablets MAD (28 days) in obese patients explored various titrations

    ASC30 tablets MAD (28 days) in obese patients explored various titrations (conducted in U.S.) Eligibility Treatment and follow up Objectives Criteria Cohort 3 ASC30: Placebo (n=8: 2) QD After 14-day safety evaluation 5mg 15mg 30mg 60mg Follow up To evaluate safety and Participants with high starting

  7. Slide 7: Once-daily tablets demonstrated superior weight loss at Day 29

    ASC30 once-daily tablets demonstrated superior weight loss at Day 29 change from baseline (%) % body weight change from baseline at Day 29 0 0.2 ASC30 MAD Cohorts 1 and 2 weight change at day Body weight 29 from baseline (Day 1 prior to first dose): -5  ASC30 MAD2 = -6.3% (n=8); -4.3***  ASC30 MAD

  8. Slide 8: 20 mg and 40 mg ASC30 demonstrated superior oral PK profile at steady state

    20 mg and 40 mg ASC30 demonstrated superior oral PK profile at steady state  Higher AUC positively correlated with greater body weight reduction Concentration-time curves of ASC30 Day 28 MAD Cohort 1 MAD Cohort 2 (N = 8) (N = 8) Dose level (mg) 2, 5, 10, 20 2, 10, 20, 40 Tmax (h) 8.000 (2.00-8.00)

  9. Slide 9: Tablets MAD GI tolerability over 28-day treatment and 7-day follow-up

    ASC30 tablets MAD GI tolerability over 28-day treatment and 7-day follow-up: no vomiting incidence in MAD cohort 1 due to 2 mg to 5 mg weekly titration strategy Severity of GI-AEs (Nausea, Vomiting, Diarrhoea and Constipation) by Treatment Over Time No. of participants with any GI-AE(s) 40 mg Follow

  10. Slide 10: Incidences of GI-AEs by Treatment Over Time

    Incidences of GI-AEs by Treatment Over Time (N=8) (N=8) (N=6) Number of any GI- AE(s) 40 mg Follow up 20 mg 10 mg 20 mg Follow up 2 mg 10 mg 5 mg 2 mg Day GI-AEs：Nausea, Vomiting, Diarrhoea and Constipation 10

  11. Slide 11: ASC30 MAD Cohorts 1 and 2 had no hepatic safety signals

    ASC30 MAD Cohorts 1 and 2 had no hepatic safety signals MAD Cohort 1 (2mg, 5mg, 10mg, 20mg) mean ALT value MAD Cohort 2 (2mg, 10mg, 20mg, 40mg) mean ALT value 50 50 ULN ULN ALT (U/L) 40 40 ALT (U/L) 30 30 20 20 10 10 0 0 012 15 29 35(EOS) 012 15 29 35(EOS) Visit Dates Visit Dates MAD Cohort 1 (2mg,

  12. Slide 12: Summary

    ASC30 Summary  ASC30 once-daily oral tablets demonstrated up to 6.5% placebo-adjusted mean body weight reduction from baseline after 28-day treatment  ASC30 tablet’s higher efficacy is supported by its higher oral drug exposures  ASC30 is safe and well tolerated with only mild-to-moderate GI AEs

  13. Slide 13: E-poster

    E-poster Presentation number: 827 ASC30, an Oral GLP-IR Biased Small Molecule Agonist Demonstrated Superior Weigh Loss in Participants with Obesity: A28-Day Multiple Ascending Dose Study in Jason Wu, Vanessa Wang Asclts Pharma (Chins) Co, Limite, Hong Kong Figur 2 Rady Wath Change ‘ASCO ian onl GLP.

  14. Slide 14: Thanks

    Thanks

Ascletis Pharma — EASD 2025 on 6ix